Literature DB >> 25643939

Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma.

Stéphanie Poulain1,2,3, Eileen M Boyle4, Sabine Tricot5, Hélène Demarquette4, Emmanuelle Doye2, Christophe Roumier2,3, Patrick Duthilleul1, Claude Preudhomme2,3, Claude Alain Maurage6, Franck Morschhauser7.   

Abstract

Entities:  

Keywords:  CXCR4; MYD88; lymphoma; mutations; primary central nervous system lymphoma

Mesh：

Substances：

Year:  2015        PMID： 25643939     DOI： 10.1111/bjh.13293

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

1.  Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma.

Authors:  Tarsheen K Sethi; Alexandra E Kovach; Natalie S Grover; Li-Ching Huang; Laura A Lee; Samuel M Rubinstein; Yang Wang; David S Morgan; John P Greer; Steven I Park; Mary Ann Thompson-Arildsen; Ashwini Yenamandra; Cindy L Vnencak-Jones; Nishitha M Reddy
Journal:  Leuk Lymphoma       Date:  2019-06-11

2.  Characterization of genomic alterations in primary central nervous system lymphomas.

Authors:  Soheil Zorofchian; Hanadi El-Achi; Yuanqing Yan; Yoshua Esquenazi; Leomar Y Ballester
Journal:  J Neurooncol       Date:  2018-08-31       Impact factor: 4.130

3.  MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas.

Authors:  Naema Nayyar; Michael D White; Corey M Gill; Matthew Lastrapes; Mia Bertalan; Alexander Kaplan; Megan R D'Andrea; Ivanna Bihun; Andrew Kaneb; Jorg Dietrich; Judith A Ferry; Maria Martinez-Lage; Anita Giobbie-Hurder; Darrell R Borger; Fausto J Rodriguez; Matthew P Frosch; Emily Batchelor; Kaitlin Hoang; Benjamin Kuter; Sarah Fortin; Matthias Holdhoff; Daniel P Cahill; Scott Carter; Priscilla K Brastianos; Tracy T Batchelor
Journal:  Blood Adv       Date:  2019-02-12

4.  Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.

Authors:  Monique C Minnema; Eva Kimby; Shirley D'Sa; Luc-Matthieu Fornecker; Stéphanie Poulain; Tom J Snijders; Efstathios Kastritis; Stéphane Kremer; Aikaterini Fitsiori; Laurence Simon; Frédéric Davi; Michael Lunn; Jorge J Castillo; Christopher J Patterson; Magali Le Garff-Tavernier; Myrto Costopoulos; Véronique Leblond; Marie-José Kersten; Meletios A Dimopoulos; Steven P Treon
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

Review 5.  [Classification of malignant lymphomas. Current situation].

Authors:  K Koch; W Klapper
Journal:  Internist (Berl)       Date:  2016-03       Impact factor: 0.743

6.  Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.

Authors:  Maxime Fontanilles; Florent Marguet; Élodie Bohers; Pierre-Julien Viailly; Sydney Dubois; Philippe Bertrand; Vincent Camus; Sylvain Mareschal; Philippe Ruminy; Catherine Maingonnat; Stéphane Lepretre; Elena-Liana Veresezan; Stéphane Derrey; Hervé Tilly; Jean-Michel Picquenot; Annie Laquerrière; Fabrice Jardin
Journal:  Oncotarget       Date:  2017-07-18

7.  Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.

Authors:  Ju-Han Lee; Hoiseon Jeong; Jung-Woo Choi; HwaEun Oh; Young-Sik Kim
Journal:  Sci Rep       Date:  2017-05-11       Impact factor: 4.379

8.  MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single-center experience.

Authors:  Olimpia E Curran; Michael T C Poon; Louise Gilroy; Antonia Torgersen; Colin Smith; Wael Al-Qsous
Journal:  Neurooncol Adv       Date:  2021-07-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.